Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.3M Buy
460,195
+293,895
+177% +$12M ﹤0.01% 1557
2025
Q4
$6.75M Sell
166,300
-4,369
-3% -$190K ﹤0.01% 2217
2025
Q3
$8.03M Sell
170,669
-2,242
-1% -$116K ﹤0.01% 2077
2025
Q2
$9.01M Sell
172,911
-7,607
-4% -$417K ﹤0.01% 1899
2025
Q1
$10.9M Sell
180,518
-8,865
-5% -$571K ﹤0.01% 1701
2024
Q4
$13M Sell
189,383
-4,101
-2% -$286K ﹤0.01% 1618
2024
Q3
$13.9M Sell
193,484
-6,323
-3% -$446K ﹤0.01% 1543
2024
Q2
$13.9M Sell
199,807
-563,321
-74% -$41.1M ﹤0.01% 1502
2024
Q1
$61.1M Sell
763,128
-195,549
-20% -$17.4M 0.02% 714
2023
Q4
$105M Sell
958,677
-8,494
-0.9% -$878K 0.03% 502
2023
Q3
$97.5M Sell
967,171
-86,907
-8% -$9.99M 0.03% 506
2023
Q2
$143M Sell
1,054,078
-296,785
-22% -$36.2M 0.04% 393
2023
Q1
$140M Buy
1,350,863
+99,568
+8% +$9.63M 0.05% 389
2022
Q4
$111M Sell
1,251,295
-123,339
-9% -$10.2M 0.04% 445
2022
Q3
$110M Buy
1,374,634
+60,175
+5% +$5.68M 0.04% 429
2022
Q2
$126M Buy
1,314,459
+83,711
+7% +$10M 0.04% 403
2022
Q1
$183M Buy
1,230,748
+74,006
+6% +$10.3M 0.05% 358
2021
Q4
$164M Buy
1,156,742
+135,342
+13% +$19.2M 0.05% 409
2021
Q3
$134M Buy
1,021,400
+123,953
+14% +$16.2M 0.04% 430
2021
Q2
$123M Buy
897,447
+142,010
+19% +$19.4M 0.04% 462
2021
Q1
$98.7M Buy
755,437
+329,938
+78% +$39.7M 0.03% 513
2020
Q4
$47.7M Buy
425,499
+17,559
+4% +$1.66M 0.02% 759
2020
Q3
$32.1M Sell
407,940
-39,467
-9% -$3.22M 0.01% 830
2020
Q2
$32.2M Buy
447,407
+237,375
+113% +$16.5M 0.01% 803
2020
Q1
$12M Buy
210,032
+245
+0.1% +$22.6K 0.01% 1256
2019
Q4
$23.5M Buy
209,787
+2,925
+1% +$312K 0.01% 1065
2019
Q3
$19.9M Sell
206,862
-1,056
-0.5% -$99.1K 0.01% 1145
2019
Q2
$17.8M Sell
207,918
-31,875
-13% -$2.62M 0.01% 1262
2019
Q1
$19.9M Sell
239,793
-3,074
-1% -$223K 0.01% 1147
2018
Q4
$15.6M Buy
242,867
+16,682
+7% +$1.14M 0.01% 1226
2018
Q3
$17.9M Buy
226,185
+12,871
+6% +$996K 0.01% 1397
2018
Q2
$15.6M Buy
213,314
+52,051
+32% +$3.54M 0.01% 1372
2018
Q1
$10.2M Buy
161,263
+8,860
+6% +$529K ﹤0.01% 1644
2017
Q4
$7.77M Sell
152,403
-2,709
-2% -$141K ﹤0.01% 1806
2017
Q3
$8.14M Buy
155,112
+13,514
+10% +$678K ﹤0.01% 1741
2017
Q2
$7.21M Buy
141,598
+10,730
+8% +$531K ﹤0.01% 1805
2017
Q1
$5.81M Buy
130,868
+5,670
+5% +$244K ﹤0.01% 1916
2016
Q4
$5.53M Buy
125,198
+1,860
+2% +$79K ﹤0.01% 1964
2016
Q3
$4.94M Sell
123,338
-2,715
-2% -$115K ﹤0.01% 1999
2016
Q2
$6.02M Buy
126,053
+4,321
+4% +$183K ﹤0.01% 1794
2016
Q1
$5.11M Buy
121,732
+2,612
+2% +$103K ﹤0.01% 1925
2015
Q4
$5.25M Sell
119,120
-2,722
-2% -$118K ﹤0.01% 1987
2015
Q3
$5.82M Sell
121,842
-9,789
-7% -$537K ﹤0.01% 1908
2015
Q2
$7.67M Buy
131,631
+2,563
+2% +$138K ﹤0.01% 1810
2015
Q1
$6.52M Buy
129,068
+4,201
+3% +$206K ﹤0.01% 1924
2014
Q4
$5.62M Buy
124,867
+3,201
+3% +$134K ﹤0.01% 1979
2014
Q3
$4.48M Sell
121,666
-281,140
-70% -$11.2M ﹤0.01% 2093
2014
Q2
$17.8M Sell
402,806
-444,884
-52% -$20.2M 0.01% 1097
2014
Q1
$36.8M Sell
847,690
-422,536
-33% -$18.8M 0.02% 665
2013
Q4
$54M Buy
1,270,226
+113,016
+10% +$4.29M 0.03% 502
2013
Q3
$39.3M Buy
1,157,210
+89,160
+8% +$2.91M 0.03% 632
2013
Q2
$33.4M Buy
+1,068,050
New +$34.7M 0.02% 698

Other funds holding CNMD

Ameriprise's CNMD Position: Q1 2026 in Review

Ameriprise increased its CONMED (CNMD) stake by 177% in Q1 2026, buying an estimated $12M and bringing the position to 460,195 shares worth $16.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1557.

Ameriprise first reported a position in CNMD in Q2 2013 and has held it in 52 quarters since. The position peaked at $183M in Q1 2022. 236 funds tracked by Wall St. Rank hold CNMD as of Q1 2026.

  • Ameriprise held 460,195 shares of CONMED worth $16.3M as of Q1 2026.
  • Ameriprise bought 293,895 CONMED shares in Q1 2026, an estimated $12M.
  • CONMED made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1557 holding.
  • Ameriprise first reported a position in CONMED in Q2 2013 and has held it in 52 quarters since.
  • Ameriprise's CONMED position peaked at $183M in Q1 2022.
  • 236 funds tracked by Wall St. Rank held CONMED as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.